Dyspnoea Worsened by Salmeterol

Congleton J. , Muers M. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and responses to bronchodilator therapy. Resp Med 1995; 89: 291–6

Dudgeon D. , Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manag 1998; 16: 212–19

Donat S. , Levy D. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160: 1347–52

Todd N. , Peters W. , Ost A. , Roggli V. , Piantadosi C. Pulmonary drug toxicity in patients with primary breast cancer treated with high dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Resp Dis 1993; 147: 1264–70

Lopez A. , Compte T. , Ferris T. Risk factors for lung toxicity in pediatric cancer survivors (Spanish). An Esp Pediat 1999; 51: 505–11

Weinberger S. , Drazen J. Disturbances of respiratory function. In: Fauci A. , Braunwald E. , Isselbacher K. Harrison's Principles of Internal Medicine, 14th edn. New York: McGraw-Hill, 1998: 1410–17

Wilkinson J. , Roberts J. , Bradding P. , Holgate S. , Howarth P. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ 1992; 305: 931–2